Suh Jee Su, Minuzzi Luciano, Cudney Lauren E, Maich William, Eltayebani Maha, Soares Claudio N, Frey Benicio N
Neuroscience Graduate Program.
Mood Disorders Program and Women's Health Concerns Clinic, St Joseph's Healthcare Hamilton, Hamilton.
Neuroreport. 2019 Mar 20;30(5):378-382. doi: 10.1097/WNR.0000000000001211.
Thickness of the cerebral cortex has been previously investigated for its potential as a biomarker in major depressive disorder (MDD). This is the first study to examine the longitudinal effects of a serotonin-norepinephrine reuptake inhibitor, desvenlafaxine succinate (DVS), on whole-brain cortical thickness (CT) in patients treated for MDD. We also aimed to replicate a previous finding of an association between improvement in clinical severity and CT in one of five predefined regions-of-interest (ROI). Twenty-five individuals with MDD received treatment with DVS (50 mg/day) for 8 weeks, with 19 completing the study. We used FreeSurfer 6.0 to compare group differences between MDD and controls (n=23) and between treatment responders, treatment nonresponders and controls. We tested correlations between 8-week change in depression severity and regional CT in five ROIs: the rostral and caudal anterior cingulate cortex, lateral and medial orbitofrontal cortex and inferior temporal gyrus. There were no differences in CT between MDD and controls or DVS responders and controls. There was greater CT in DVS nonresponders in the left pars orbitalis when compared to controls [MNI (X, Y, Z=-38.4, 37.6, -11.1); P=0.027]. There were no significant correlations between change in depression severity and CT in any of the five ROIs. Brain CT does not seem to be a sensitive marker of short-term antidepressant response in MDD, except increased CT in nonresponders. Duration of the intervention and interindividual heterogeneity may impede identification of discriminating features of treatment response as associated to CT.
大脑皮层厚度此前已被研究其作为重度抑郁症（MDD）生物标志物的潜力。这是第一项研究，旨在探讨5-羟色胺-去甲肾上腺素再摄取抑制剂琥珀酸去甲文拉法辛（DVS）对接受MDD治疗患者全脑皮层厚度（CT）的纵向影响。我们还旨在重复先前在五个预定义感兴趣区域（ROI）之一中发现的临床严重程度改善与CT之间关联的研究结果。25名MDD患者接受DVS（50mg/天）治疗8周，其中19名完成研究。我们使用FreeSurfer 6.0比较MDD患者与对照组（n = 23）之间以及治疗反应者、治疗无反应者与对照组之间的组间差异。我们测试了五个ROI中抑郁症严重程度8周变化与区域CT之间的相关性：喙侧和尾侧前扣带回皮层、外侧和内侧眶额皮层以及颞下回。MDD患者与对照组之间或DVS反应者与对照组之间的CT没有差异。与对照组相比，DVS无反应者左侧眶部的CT更大[MNI（X，Y，Z = -38.4，37.6，-11.1）；P = 0.027]。五个ROI中任何一个区域的抑郁症严重程度变化与CT之间均无显著相关性。除了无反应者CT增加外，脑CT似乎不是MDD短期抗抑郁反应的敏感标志物。干预持续时间和个体间异质性可能会妨碍识别与CT相关的治疗反应的鉴别特征。
